ARQT Form 144: Insider reports two 10,000-share sales
Arcutis Biotherapeutics (ARQT) reported proposed sales of Common Stock under a Form 144 by Howard Welgus.
Rhea-AI Filing Summary
Arcutis Biotherapeutics (ARQT) reported proposed sales of Common Stock under a Form 144 by Howard Welgus. The filing lists two recent dispositions: 10,000 shares sold on 03/02/2026 for $256,517.50 and 10,000 shares sold on 02/02/2026 for $250,482.69. The notice also references 10,000 shares tied to a prior stock option exercise on 06/04/2018.
Positive
- None.
Negative
- None.
Insights
Form 144 discloses proposed insider sales and past dispositions by the named holder.
The filing lists proposed and completed sales by Howard Welgus, including two recorded dispositions of 10,000 shares each on 03/02/2026 and 02/02/2026
These entries reflect routine insider liquidity reporting requirements; cash proceeds are shown next to each past sale. Additional context about remaining holdings or any trading plan is not provided in the excerpt.
Key Figures
Key Terms
Form 144 regulatory
stock option exercise financial
Common market
FAQ
What does Arcutis Biotherapeutics' (ARQT) Form 144 show?
Who is the reporting person on the ARQT Form 144?
Are proceeds from the sales disclosed in the ARQT excerpt?
AI-generated analysis. How Rhea-AI works. Not financial advice.